Article
Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.
Haematologica - 1 Jul 2016
Baer Constance, Kern Wolfgang, Koch Sarah, Nadarajah Niroshan, Schindela Sonja, Meggendorfer Manja, Haferlach Claudia, Haferlach Torsten
Abstract excerpt
Chronic myeloid leukemia cells acquire resistance to tyrosine kinase inhibitors through mutations in the ABL1 kinase domain. The T315I mutation mediates resistance to imatinib, dasatinib, nilotinib and bosutinib, whereas sensitivity to ponatinib remains. Mutation detection by conventional Sanger sequencing requires 10%-20% expansion of the mutated subclone. We studied the T315I mutation development by ultra-deep...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.